ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 31747009

INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma.

Van Den Bent M and 24 others. Neuro Oncol, 2020. Cited by 161 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma. Papers, record 31747009. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/31747009

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma.
PubMed
Journal
Neuro Oncol
PubMed
Year
2020
PubMed
Publication types
Clinical Trial, Phase II, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
161
iCite
Relative citation ratio, by iCite
7.35
iCite
Revised in PubMed
2021-08-02
PubMed

Authors25

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Van Den Bent MMartin
2Eoli MMarica
3Sepulveda JMJuan Manuel
4Smits MMarion
5Walenkamp AAnnemiek
6Frenel JSJean-Sebastian
7Franceschi EEnrico
8Clement PMPaul M
9Chinot OOlivier
10De Vos FFilip

1 to 10 of 25Source PubMed

See all 25 authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Brain NeoplasmsMajor topic
GlioblastomaMajor topic
Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Alkylating
ErbB Receptors
Humans
Lomustine
Temozolomide

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT02343406Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade GliomasDerived from the trialYes

Source ClinicalTrials.gov

Comments and corrections2

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn PapersSource
Erratum in32,609,812Corrigendum to INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma.https://conductscience.org/library/papers/32609812PubMed
Comment in32,144,420A troublesome burden, the amplification of EGFR in glioblastoma!https://conductscience.org/library/papers/32144420PubMed

References26

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
128,575,464Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification.Neuro Oncol2017https://conductscience.org/library/papers/28575464PubMed
219,901,104MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951.J Clin Oncol2009https://conductscience.org/library/papers/19901104PubMed
311,070,098Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.N Engl J Med2000https://conductscience.org/library/papers/11070098PubMed
429,075,855Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study.Cancer Chemother Pharmacol2017https://conductscience.org/library/papers/29075855PubMed
523,940,216Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.J Clin Oncol2013https://conductscience.org/library/papers/23940216PubMed
624,670,608Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma.Neuro Oncol2014https://conductscience.org/library/papers/24670608PubMed
721,471,286Pathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib--a phase II trial.Mol Cancer Ther2011https://conductscience.org/library/papers/21471286PubMed
820,231,676Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.J Clin Oncol2010https://conductscience.org/library/papers/20231676PubMed
928,855,349Epidermal Growth Factor Receptor Variant III (EGFRvIII) Positivity in EGFR-Amplified Glioblastomas: Prognostic Role and Comparison between Primary and Recurrent Tumors.Clin Cancer Res2017https://conductscience.org/library/papers/28855349PubMed
1026,250,565Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials.Neuro Oncol2015https://conductscience.org/library/papers/26250565PubMed

1 to 10 of 26

See all 26 references

Cited by133

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 161 citations.

PMIDTitleJournalYearIn PapersSource
42,958,602Glioblastoma as a dynamic tumor ecosystem: from molecular alterations to therapeutic translation.Exp Hematol Oncol2026https://conductscience.org/library/papers/42958602PubMed
42,888,247EGFR-targeted antibody-toxin conjugate in recurrent glioma: a phase 1 trial.Nat Med2026https://conductscience.org/library/papers/42888247PubMed
42,824,982Receptor tyrosine kinase targeted therapies in glioblastoma: a systematic review.Front Med (Lausanne)2026https://conductscience.org/library/papers/42824982PubMed
42,618,642Exploring the landscape of targetable alterations in patients with glioblastoma.Nat Rev Clin Oncol2026https://conductscience.org/library/papers/42618642PubMed
42,616,271Establishment and functional characterization of an EGFR-amplified tumoroid from squamous cell carcinoma of unknown primary.Hum Cell2026https://conductscience.org/library/papers/42616271PubMed
42,283,227Predictive value of EGFR amplification and EGFRvIII mutation in EGFR-targeted therapy for recurrent glioblastoma: a systematic review.CNS Oncol2026https://conductscience.org/library/papers/42283227PubMed
42,251,229Post-recurrence management of malignant glial brain tumors: therapeutic strategies, evidence and limitations, palliative care, terminal sedation, and end-of-life considerations.Clin Transl Oncol2026https://conductscience.org/library/papers/42251229PubMed
42,180,101Antibody-drug conjugates for primary brain tumors.Front Oncol2026https://conductscience.org/library/papers/42180101PubMed
41,874,881Recent Advances in Targeted Therapies for Adult Gliomas.Curr Neurol Neurosci Rep2026https://conductscience.org/library/papers/41874881PubMed
41,825,107Rational payload selection enables high antitumoral efficacy of an anti-EGFR antibody-drug conjugate against ovarian tumors.Neoplasia2026https://conductscience.org/library/papers/41825107PubMed

1 to 10 of 133

See all 133 cited by

Genes7

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
EGFR1,956PubTator's text mininghttps://conductscience.org/library/genes/1956NCBI Gene
H1-13,024PubTator's text mininghttps://conductscience.org/library/genes/3024NCBI Gene
H1-23,006PubTator's text mininghttps://conductscience.org/library/genes/3006NCBI Gene
H1-53,009PubTator's text mininghttps://conductscience.org/library/genes/3009NCBI Gene
H2BC218,349PubTator's text mininghttps://conductscience.org/library/genes/8349NCBI Gene
MGMT4,255PubTator's text mininghttps://conductscience.org/library/genes/4255NCBI Gene
TUBA3D113,457PubTator's text mininghttps://conductscience.org/library/genes/113457NCBI Gene

Drugs2

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targetsSource
DEPATUXIZUMAB MAFODOTINCHEMBL3707277Derived from the trial1https://conductscience.org/library/drugs/CHEMBL3707277ChEMBL
TEMOZOLOMIDECHEMBL810Derived from the trial1https://conductscience.org/library/drugs/CHEMBL810ChEMBL

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/31747009

GET https://conductscience.org/api/papers/v1/31747009/authors?page=2

API referenceFor AI assistants